Crohn's & colitis 360
Cure8 research brief
Why This Matters
This study compares two commonly used anti‑TNF biologics in children with Crohn’s disease using real‑world prospective data, so its findings are directly relevant to treatment choice, expectations for 1‑year remission, and decisions about combining an immunomodulator.
Who Should Pay Attention
Pediatric patients with Crohn’s disease, parents and caregivers, pediatric gastroenterologists, and clinicians who prescribe biologics.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a prospective, multicenter real-world cohort study (PIBD-SETQuality) comparing two anti-TNF biologics — infliximab and adalimumab — in children (age 3–18) with luminal Crohn’s disease who were biologic‑naïve and had ≥1 year follow-up. The primary outcome was steroid‑free clinical remission (SFCR) at 12 months.
At one year, SFCR rates were similar: 61% (34/56) with adalimumab and 55% (66/120) with infliximab; the risk ratio did not reach statistical significance. The study also reports that, among children receiving a concomitant immunomodulator, adalimumab was associated with a lower adjusted hazard of treatment discontinuation than infliximab.
The data come from a registered prospective cohort (ClinicalTrials.gov NCT03571373) collected between 2017 and 2024 across multiple centers. As an observational real‑world study, it reflects routine practice and includes clinical outcomes over the first treatment year.
If you are a caregiver or clinician considering anti‑TNF therapy for a child with Crohn’s disease, this study suggests broadly similar 1‑year effectiveness between infliximab and adalimumab in achieving steroid‑free remission, with a possible advantage for adalimumab in drug persistence when given with an immunomodulator.
Discussing individual risks, administration method, monitoring plans (including drug levels), and preferences with your treating team remains important.
Keep In Mind
This is an observational cohort (not a randomized trial); differences in patient selection, dosing, and monitoring can affect outcomes. The article reports 1‑year results; longer-term effectiveness, safety, and growth or development outcomes were not detailed in the abstract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCrohn's & colitis 360
AuthorsVuijk SA, Klomberg RCW, Katgert E +11 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 3, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
TNF inhibitors might help prevent serious complications in kids with Crohn's Disease
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...